You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors

Citation Tools

Article menu
XML
Immunotherapy biomarkers
Original research
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Zhou J, Donaubauer A, Frey B, et al
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer 2021;9:e001845. doi: 10.1136/jitc-2020-001845